Aeglea Biotherapeutics, Inc.

Aeglea Biotherapeutics, Inc. 901 S. Mopac Expressway, Barton Oaks Plaza One Suite 250 Austin, TX 78746
Locations Update This Record Cases by Outcome Cases by Type	SEC CIK 1636282

Add a document

Description
Summary
Document Type	Academic Paper Corporate Document - Internal Corporate Document - Public Court Document Equity Research Government Document - Federal Government Document - State Government Document - Local FBI File Public Records Request Response - FOIA Public Records Request Response - State Non-Profit Report Police Report White Paper
Document Date
Document Source
Source URL
File
	If you would like to be credited for contributing this document, make sure to sign in or sign up first. Once uploaded, your document may not be immediately visible to the public as we review each document for legal issues. Thanks for your patience!

Go Pro to view an analysis and graphs of case roles, types and more.

Aeglea Biotherapeutics, Inc. has not been involved in any litigation in the PlainSite database.

Inside Counsel (0)

Go Pro to view corporate inside counsel.

Outside Counsel (0)

This table is empty.

Filter By Form All Records 10-K 10-Q 3 3/A 4 4/A 424B4 424B5 8-A12B 8-K CERTNAS CORRESP CT ORDER D DEF 14A DRS EFFECT POS AM S-1 S-1/A S-3 S-3/A S-8 SC 13G SC 13G/A UPLOAD From To

	Date	Entity	Form Number	Description
	11/5/2025	Turtle Cameron	4	Statement of changes in beneficial ownership of securities
	11/4/2025		8-K	Current report pursuant to Section 13 or 15(d)
	11/4/2025		10-Q
	11/3/2025		144	Notice of proposed sale of securities pursuant to Rule 144 under...
	10/17/2025		SCHEDULE 13D/A
	10/15/2025		8-K	Current report pursuant to Section 13 or 15(d)
	10/14/2025		8-K	Current report pursuant to Section 13 or 15(d)
	10/14/2025		424B5
	10/14/2025		424B5
	9/3/2025	Burrows Scott L	4	Statement of changes in beneficial ownership of securities
	8/5/2025		S-8
	8/5/2025		8-K	Current report pursuant to Section 13 or 15(d)
	8/5/2025		10-Q
	7/29/2025		SCHEDULE 13G
	7/16/2025		SCHEDULE 13G/A
	6/17/2025		8-K	Current report pursuant to Section 13 or 15(d)
	6/2/2025		UPLOAD
	6/2/2025		8-K	Current report pursuant to Section 13 or 15(d)
	6/2/2025	Fairmount Healthcare Fund II L.P.	4	Statement of changes in beneficial ownership of securities
	6/2/2025	Stelzer Laurie	4	Statement of changes in beneficial ownership of securities
	6/2/2025	Milligan, Sandra	4	Statement of changes in beneficial ownership of securities
	6/2/2025	McKenna Mark C.	4	Statement of changes in beneficial ownership of securities
	6/2/2025	Henderson Michael Thomas	4	Statement of changes in beneficial ownership of securities
	6/2/2025	Albers Jeffrey W.	4	Statement of changes in beneficial ownership of securities
	5/21/2025		CORRESP
	5/9/2025		UPLOAD
	5/8/2025		8-K	Current report pursuant to Section 13 or 15(d)
	5/8/2025		10-Q
	5/1/2025		SCHEDULE 13G
	4/14/2025		DEFA14A
	4/14/2025		DEF 14A
	4/14/2025		ARS
	3/13/2025		EFFECT
	3/7/2025		EFFECT
	3/7/2025		POS AM
	3/6/2025		8-K	Current report pursuant to Section 13 or 15(d)
	3/5/2025		CORRESP
	3/4/2025		UPLOAD
	2/27/2025		S-8
	2/27/2025		S-3
	2/27/2025		8-K	Current report pursuant to Section 13 or 15(d)
	2/27/2025		10-K	Annual report pursuant to Section 13 or 15(d)
	2/14/2025		SCHEDULE 13G/A
	2/14/2025		SCHEDULE 13G/A
	2/14/2025		SCHEDULE 13G/A
	1/17/2025	Burrows Scott L	4	Statement of changes in beneficial ownership of securities
	1/17/2025	Sloan, Sheldon	4	Statement of changes in beneficial ownership of securities
	1/17/2025	Turtle Cameron	4	Statement of changes in beneficial ownership of securities
	1/17/2025	King-Jones Heidy	4	Statement of changes in beneficial ownership of securities
	1/14/2025	Henderson Michael Thomas	4	Statement of changes in beneficial ownership of securities

715 Rows Total	Page 1 of 15 | Go To

	Date Recorded	Party	Role	Document Type	Document No.	Invention Title
	4/8/2025	Spyre Therapeutics, Inc.	Assignee	Application Publication	18000183 20240058429	Treatment Of Homocystinuria And Hyperhomocysteinemia Using Cystathionine... Treatment Of Homocystinuria And Hyperhomocysteinemia Using Cystathionine...
	10/3/2023	Immedica Pharma Ab	Assignee	Application Publication	17286041 20210379167	Arginine Depletion Therapy For Treatment of GAMT Deficiency Arginine Depletion Therapy For Treatment of GAMT Deficiency
	10/2/2023	Immedica Pharma Ab	Assignee	Application Application Application Application Publication Publication Publication Publication Patent Patent	17006383 16210248 15699951 17286041 20190167770 20180177853 20210379167 20210189371 11717562 10729752	Methods For Production Of Human Recombinant Arginase 1 And Uses Thereof Compositions and Methods for Treating Cancer with Arginine Depletion and... Method And Composition For Treating Arginase 1 Deficiency Compositions and Methods for Treating Cancer with Arginine Depletion and... Method And Composition For Treating Arginase 1 Deficiency Methods For Production Of Human Recombinant Arginase 1 And Uses Thereof Compositions and Methods for Treating Cancer with Arginine Depletion and... Method And Composition For Treating Arginase 1 Deficiency
	10/2/2023	Immedica Pharma Ab	Assignee	Application Application Application Application Application Publication Publication Publication Publication Publication Patent Patent	17286041 17006383 18344083 16210248 15699951 20240009284 20190167770 20180177853 20210379167 20210189371 11717562 10729752	Compositions and Methods for Treating Cancer with Arginine Depletion and... Method And Composition For Treating Arginase 1 Deficiency Methods For Production Of Human Recombinant Arginase 1 And Uses Thereof Arginine Depletion Therapy For Treatment of GAMT Deficiency Compositions and Methods for Treating Cancer with Arginine Depletion and... Method And Composition For Treating Arginase 1 Deficiency Method And Composition For Treating Arginase 1 Deficiency Compositions and Methods for Treating Cancer with Arginine Depletion and... Method And Composition For Treating Arginase 1 Deficiency Method And Composition For Treating Arginase 1 Deficiency Methods For Production Of Human Recombinant Arginase 1 And Uses Thereof Arginine Depletion Therapy For Treatment of GAMT Deficiency
	3/8/2022	Rowlinson, Scott W.	Assignor	Application Publication	17006383 20210189371	Methods For Production Of Human Recombinant Arginase 1 And Uses Thereof Methods For Production Of Human Recombinant Arginase 1 And Uses Thereof
	9/5/2018	Aerase, Inc.	Assignee	Application Publication	15699951 20180177853	Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and...
	9/5/2018	Aerase, Inc.	Assignee	Application Publication Patent	15699951 20180177853 10729752	Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and...
	7/13/2018	Lowe, David	Assignor	Application Publication	15699951 20180177853	Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and...
	7/13/2018	Rowlinson, Scott W.	Assignor	Application Publication	15699951 20180177853	Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and...
	7/13/2018	Alters, Susan	Assignor	Application Publication	15699951 20180177853	Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and...
	7/13/2018	Agnello, Giulia	Assignor	Application Publication	15699951 20180177853	Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and...
	7/13/2018	Lowe, David	Assignor	Application Publication Patent	15699951 20180177853 10729752	Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and...
	7/13/2018	Rowlinson, Scott W.	Assignor	Application Publication Patent	15699951 20180177853 10729752	Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and...
	7/13/2018	Alters, Susan	Assignor	Application Publication Patent	15699951 20180177853 10729752	Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and...
	7/13/2018	Agnello, Giulia	Assignor	Application Publication Patent	15699951 20180177853 10729752	Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and... Compositions and Methods for Treating Cancer with Arginine Depletion and...

15 Rows Total

	Date Recorded	Party	Role	Document Type	Document No.	Image
	5/10/2024	Spyre Therapeutics, Inc.	Assignee	Application	98251421
	5/10/2024	Spyre Therapeutics, Inc.	Assignee	Trademark	0
	5/10/2024	Spyre Therapeutics, Inc.	Assignee	Trademark	0
	5/10/2024	Spyre Therapeutics, Inc.	Assignee	Application	98251414
	5/10/2024	Spyre Therapeutics, Inc.	Assignee	Application	98251410
	5/10/2024	Spyre Therapeutics, Inc.	Assignee	Trademark	0

6 Rows Total

Competitors (0)

There are no organizations to display.

Corporate Family (45)

Track Corporate Family

• Albers Jeffrey W., None
• Alspaugh, Jonathan, None
• Baker, Julian, None
• Brownstein Sara, None
• Bruhn Suzanne Louise, None
• Burrows Scott L, None
• Cox Russell J., None
• Fairmount Healthcare Fund II L.P., None
• Georgiou, George, None
• Goldberg Jeff Marc, None
• Hanley Jr. Michael Conick, None
• Harwin Peter Evan, None
• Hebel, Henry, None
• Henderson Michael Thomas, None
• Isaly Samuel D, None
• Kastenmayer James Paul, None
• King-Jones Heidy, None
• Lawlis V Bryan, None
• Lawton Alison Francis, None
• LILLY ELI & CO, None
• Lowe David George, None
• Mahatme Sandesh, None
• Maravic Magovcevic Ivana, None
• McKenna Mark C., None
• Milligan, Sandra, None
• Neuman, Linda L., None
• Novartis AG, None
• Novartis Bioventures Ltd., None
• Quinn, Anthony, None
• Rao Madduri Ravin, None
• Rojas-caro, Sandra, None
• Rowlinson, Scott W., None
• Schuchart Aaron, None
• Shanafelt Armen, None
• Sloan Leslie, None
• Sloan, Sheldon, None
• Smith Hunter C, None
• Souza, Marcio, None
• Stelzer Laurie, None
• Torres S. Edward, None
• Turtle Cameron, None
• Tyler, Joseph E., None
• Weber, Steven, None
• Wooldridge James, None
• York Charles N II, None

Subsidiaries

• Cox Russell J.
• Lowe David George
• Novartis AG
• Quinn, Anthony
• Rowlinson, Scott W.
• Tyler, Joseph E.
• York Charles N II
• LILLY ELI & CO
• Georgiou, George
• Hebel, Henry
• Mahatme Sandesh
• Rojas-caro, Sandra
• Shanafelt Armen
• Bruhn Suzanne Louise
• Isaly Samuel D
• Schuchart Aaron
• Wooldridge James
• Maravic Magovcevic Ivana
• Novartis Bioventures Ltd.
• Lawlis V Bryan
• Sloan Leslie
• Hanley Jr. Michael Conick
• Rao Madduri Ravin
• Lawton Alison Francis
• Torres S. Edward
• Weber, Steven
• Brownstein Sara
• Baker, Julian
• Souza, Marcio
• Alspaugh, Jonathan
• Smith Hunter C
• Kastenmayer James Paul
• Goldberg Jeff Marc
• Neuman, Linda L.
• Henderson Michael Thomas
• Turtle Cameron
• Fairmount Healthcare Fund II L.P.
• Burrows Scott L
• King-Jones Heidy
• Stelzer Laurie
• Albers Jeffrey W.
• McKenna Mark C.
• Milligan, Sandra
• Harwin Peter Evan
• Sloan, Sheldon

Sign in to add additional links.

Incoming Payments

This organization has not disclosed any incoming payments from lobbying groups.

Outgoing Payments

This organization has not disclosed any outgoing payments to lobbying groups.